Bolouri H’s study on nearly 1,000 participants revealed that somatic structural variants are more prevalent in younger AML patients, with genetic mutations such as GATA2, FLT3, and CBL highlighting the need for age-specific therapeutic strategies (22). Here, FLT3 is linked to acute myeloid leukemia.